Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethinyl estradiol + norelgestromin is a transdermal contraceptive patch containing two active hormones: ethinyl estradiol (an estrogen) and norelgestromin (a progestin). It is primarily used for the prevention of pregnancy. The patch works by inhibiting ovulation (preventing the release of an egg from the ovary), thickening cervical mucus to block sperm entry into the uterus, and altering the endometrial lining to reduce the likelihood of implantation. The medication is applied as a skin patch once weekly for three consecutive weeks followed by a one-week patch-free interval. It may be less effective in individuals with a body weight over 198 pounds (90 kg) or BMI ≥30 kg/m²[1][2][3][4][5]. Common side effects include headache, nausea, breast tenderness, and irregular uterine bleeding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinyl estradiol + norelgestromin.